HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pachner, A. R. Articles by Pak, E. Search for Related Content PubMed PubMed Citation Articles by Pachner, A. R. Articles by Pak, E. Related Collections Gene expression studies All Immunology Autoimmune diseases Parasitic infections

Multiplex analysis of expression of three IFNß-induced genes in antibody-positive MS patients

From the University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, NJ.

Address correspondence and reprint requests to Dr. Andrew R. Pachner, Department of Neurology and Neurosciences, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103; e-mail: pachner{at}umdnj.edu

Some interferon beta (IFNß)–treated patients with multiple sclerosis develop antibody-mediated decreased bioactivity with resultant loss of therapeutic effect. The authors developed real-time multiplex reverse transcriptase PCR to measure expression of three IFNß-inducible genes to directly assess IFNß bioactivity in patients with neutralizing antibodies (NAbs). The three genes responded in tandem. Correlation of NAb level with bioactivity at low/moderate NAb levels was poor, indicating that for such patients, direct measurement of IFNß bioactivity is most reliable.

The study was funded by grants from the National Multiple Sclerosis Society (RG3402), Biogen Idec, Pfizer/Serono, and Berlex.

Disclosure: Dr. Pachner has received honoraria from Berlex, Serono, Biogen, and Teva and has received grant support for research from Berlex, Serono, and Biogen. Ms. Narayan and Ms. Pak report no conflicts of interest.

Received July 26, 2005. Accepted in final form October 19, 2005.

This article has been cited by other articles:

				F Sellebjerg, P Datta, J Larsen, K Rieneck, I Alsing, A Oturai, A Svejgaard, P Soelberg Sorensen, and L. Ryder Gene expression analysis of interferon-{beta} treatment in multiple sclerosis Multiple Sclerosis, June 1, 2008; 14(5): 615 - 621. [Abstract] [PDF]

				S. Malucchi, F. Gilli, M. Caldano, F. Marnetto, P. Valentino, L. Granieri, A. Sala, M. Capobianco, and A. Bertolotto Predictive markers for response to interferon therapy in patients with multiple sclerosis Neurology, March 25, 2008; 70(13_Part_2): 1119 - 1127. [Abstract] [Full Text] [PDF]

				A.R. Pachner Neutralizing anti-IFN{beta} antibodies: clarity and confusion Multiple Sclerosis, November 1, 2007; 13(9): 1081 - 1082. [PDF]

				A. R. Pachner and D. S. Goodin Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, October 9, 2007; 69(15): 1555 - 1556. [Full Text] [PDF]

				A.R. Pachner Real-time TaqMan assay for myxovirus resistance protein (MxA) mRNA: a robust marker of interferon beta bioactivity in patients with multiple sclerosis Multiple Sclerosis, May 1, 2007; 13(1_suppl): 49 - 52. [Abstract] [PDF]

				L. A. Hoffmann, M. Krumbholz, H. Faber, T. Kuempfel, M. Starck, W. Pollmann, E. Meinl, and R. Hohlfeld Multiple sclerosis: Relating MxA transcription to anti-interferon-{beta}-neutralizing antibodies Neurology, March 20, 2007; 68(12): 958 - 959. [Full Text] [PDF]